The transcription factor retinoic acid receptor ␤ 2 (RAR␤ 2 ) is a potent inhibitor of breast cancer cells in vitro, and studies suggest that RAR␤ expression is lost in primary breast cancer. Although RAR␤ 2 is selectively downregulated at the mRNA level in breast tumor cells, we show that expression of an RAR␤ protein is elevated in five of five breast tumor cell lines relative to normal human mammary epithelial cells. Subsequent analysis identified this protein as the translation product of the human RAR␤ 4 transcript. Unlike the previously characterized mouse RAR␤ 4 isoform, the human RAR␤ 4 retains only half of a DNA-binding domain and lacks a ligand-independent transactivation domain at its N terminus. The RAR␤ 4 protein localizes to the cytoplasm and to subnuclear compartments that resemble nuclear bodies. The structure and preliminary characterizations of human RAR␤ 4 , coupled with the observation that its expression is greatly elevated in breast tumor cell lines, support the hypothesis that RAR␤ 4 functions as a dominant-negative repressor of RAR-mediated growth suppression.
Retinoids are a class of lipid-soluble micronutrients that mediate cellular signals critical for embryonic morphogenesis, cell growth, and differentiation. Retinoid signals are transduced by two families of retinoid-activated transcription factors: retinoic acid receptors (RARs) and retinoid X receptors (RXRs). RARs and RXRs are members of the nuclear receptor superfamily. Both the RAR and RXR families are composed of three genes (␣, ␤, and ␥) that generate multiple RAR and RXR isoforms by using two promoters (P1 and P2) and alternative splicing (1, 2) . For most retinoid-inducible genes, transcriptional activation occurs through RAR-RXR heterodimers acting at a retinoic acid-or retinoid X-response element (RAREs and RXREs, respectively) in the presence of biologically active metabolites (e.g., all-trans-retinoic acid or 9-cis-retinoic acid) of vitamin A (retinol).
Based on homology with other members of the steroid hormone receptor superfamily, six distinct domains (A-F) have been identified within RARs and RXRs (3) . These domains contain functional units of the transcription factor (4), including a ligand-independent transcription activation function-1, AF-1 (regions A and B); a DNA-binding domain (region C); a hinge region with roles in nuclear translocation and corepressor binding (region D); and a domain involved in dimerization, ligand binding, and ligand-dependent transcriptional activation, AF-2 (region E). The role of region F is unknown. The greatest diversity of protein sequences between RAR isoforms is generated at the N terminus by the incorporation of unique A regions with the use of alternative splicing and different promoters. Isoforms of a given RAR gene generally contain identical protein sequences B-F.
There is strong evidence that of the three RAR genes, RAR␤ has the central role in the growth regulation of mammary epithelial cells. RAR␤ maps to chromosome 3p24, a region that exhibits a high frequency (45%) of loss of heterozygosity in primary breast tumors (5) . We and others find selective loss of RAR␤ in tumorigenesis (6) (7) (8) . Retroviral transduction of breast tumor cell lines with RAR␤ 2 results in an inhibition of tumor cell proliferation (9) . Other neoplasias also exhibit loss of RAR␤ expression, including lung neoplasias (10) , premalignant oral lesions (11) , and cervical (12) , ovarian (13) , and prostate neoplasias (14) . These findings suggest that RAR␤ 2 plays a role in limiting the growth of many cell types and that the loss of this regulatory activity is associated with tumorigenesis.
The human RAR␤ gene [NR1B2, according to current nomenclature for the nuclear receptor superfamily (15) ], consists of 12 exons and two promoters, P1 and P2. P1 is the 5Ј-most promoter and directs transcription of RAR␤ 1 , which includes exons 1-4 and 6-12 (16) . P2 is located within intron 4 and promotes transcription of RAR␤ 2 (exons 5-12). Loss of RAR␤ 2 in breast tumorigenesis may occur by transcriptional down-regulation at P2 (7, 17) . Transcriptional activation of P2 is induced by retinoic acid through an RARE at Ϫ55 to Ϫ39, relative to the start of transcription (␤RARE), in close proximity to the TATA box. In electrophoretic gel mobility shift assays, unique complexes are observed in breast tumor cell lines compared with normal human mammary epithelial cells (HMECs) upon ␤RARE incubation with nuclear protein extracts (7) . In this report, we describe efforts to ascertain whether aberrant RARs or RXRs are present in breast tumor cells that may suppress RAR␤ 2 transcription. This effort led to the identification of a human RAR␤ protein, RAR␤ 4 , that is up-regulated in breast tumor cell lines.
MATERIALS AND METHODS
Cell Lines and Reagents. The normal HMEC strain AG11132 was obtained from the Coriell Institute (National Institutes of Aging Cell Repository, Camden, NJ). Breast tumor cell lines Hs578T, MCF-7, MDA-MB-231, and ZR-75-1 were obtained from the American Type Tissue Collection (Manassas, VA). MDA-MB-435 tumor cells were a gift from J. Price (18) . Cells were cultured by using media described elsewhere (19) . Retinoids were not removed from sera. For each experiment, cells from a single T75 culture flask were expanded to 5 ϫ 150 mm tissue culture dishes and harvested in parallel for subsequent RNA and protein extraction.
Identification of the Human RAR␤ 4 Transcript in Breast Tumor Cells. Total RNA was extracted from AG11132 and MDA-MB-435 cells as described (7) . Reverse transcription (RT) of RNA (5 g) from MDA-MB-435 and AG11132 cells
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked ''advertisement'' in accordance with 18 U.S.C. §1734 solely to indicate this fact.
PNAS is available online at www.pnas.org.
Abbreviations: HMECs, human mammary epithelial cells; RAR, retinoic acid receptor; RARE, RAR-binding element; RT, reverse transcription; RXR, retinoid X receptor; UTR, untranslated region. Data deposition: The sequence reported in this paper has been deposited in the GenBank database (accession no. AF157483). § To whom reprint requests should be addressed at: Box 357470, 1959 N.E. Pacific Street, Seattle, WA 98195. e-mail: kswiss@u. washington.edu.
was performed (SuperScript II, GIBCO͞BRL) with a reverse primer located 2270 bp 3Ј of the RAR␤ 2 transcription start site (2270RP; 5Ј-ACCTAGGTAGACGTGTACAG-3Ј). Primer locations are diagrammed relative to the RAR␤ 2 transcript in Fig. 3 . Nested PCR amplifications were performed (eLONGase, GIBCO͞BRL). The initial PCR contained 2 l of the RT reaction, primers 26FP (5Ј-TGTTCAGAGGCAG-GAGGGTC-3Ј) and 2270RP in 1.8 mM MgSO 4 eLONGase buffer, and were amplified 35 cycles at 94°C (30 sec), 58°C (30 sec), and 68°C (2 min 30 sec). A second PCR was performed as above with 4 l of the first reaction as the template. Primers used in the subsequent reaction were 110FP (5Ј-AACGC-GAGCGATCCGAGCAG-3Ј) and 2107RP (5Ј-TGACT-GGGTCTTTGCCATGC-3Ј). DNA bands of Ϸ2 kb and 1.65 kb were gel purified and ligated into pCR2.1 (Invitrogen) to create plasmids pCR(RAR␤ 2 ) and pCR(RAR␤ 4 ), respectively. Inserts were cycle sequenced (dRhodamine, PerkinElmer Applied Biosystems) and analyzed (ABI 377 Prism, Perkin-Elmer Applied Biosystems).
Plasmids. For in vitro translation assays, RAR␤ constructs were cloned into vector pSP64(PolyA) (Promega). Inserts were created by PCR amplification of pSG5(RAR␤) (20) or pCR(RAR␤ 4 ), by using oligonucleotides with 5Ј chimeric restriction enzyme cleavage sites. (In the following five primers, the translation start sites, if any, of the respective isoforms are boldface and the enzyme cleavage sites are italicized.) All of the PCRs used the reverse primer SacI-RAR␤ RP (5Ј-TTGG-GAGCTCTTATTGCACGAGTGGTGAC-3Ј; the SacI site is italicized). PCRs were performed with the eLONGase enzyme mix. For the RAR␤ 2 coding sequence, PCR of pSG5(RAR␤) was performed by using the forward primer BamHI-RAR␤ 2 (5Ј-GGATCCAGGGAGATCATGTTTGACTGTATGG-3Ј). Two forward primers were used to generate a coding sequence downstream of the CUG at nucleotide 259 of the RAR␤ 4 mRNA; BamHI-wt-RAR␤ 4 259 (5Ј-TAGAGGATCCGCCGAGCAAG-CCTGG-3Ј) and BamHI-mut-RAR␤ 4 259 (5Ј-TAGAGGATCC GCCGAGCAAGCATGG-3Ј). The latter oligonucleotide alters the CUG initiation site to AUG. The coding sequence downstream of the AUG at nucleotide 448 of the RAR␤ 4 transcript was amplified by PCR of pSG5(RAR␤) with the forward primer BamHI-RAR␤ 4 448 (5Ј-GGATCCCAGAA-GAATATGATTTACACTTGTCACC-3Ј). PCR products were gel purified, digested with BamHI and SacI, and ligated into the BamHI and SacI sites of pSP64(PolyA) to create pSP(RAR␤ 2 ), pSP(RAR␤ 4 259wt), pSP(RAR␤ 4 259mut), and pSP(RAR␤ 4 448), respectively.
The eukaryotic expression vector pSecTag (Invitrogen), containing a multiple cloning site 5Ј of a Myc epitope and six histidine residues [(His) 6 ], was modified to remove the secretory signal as follows: pSecTag was digested with KpnI and the resulting 3Ј overhanging nucleotides were removed with exonuclease. After an NheI digestion and a Klenow fill-in reaction, the blunt-ended linearized vector (pTag) was religated. PCR amplification of pSG5(RAR␤) used chimeric primers to construct restriction enzyme recognition sites adjacent to the amplified RAR␤ sequence. All PCR amplifications used the reverse primer RAR␤ pTag (5Ј-CCCTCTAGATTGCACGAGTGGTGACTG-3Ј; the XbaI restriction site is italicized). The forward primers BamHI-RAR␤ 2 and BamHI-RAR␤ 4 448 (above) were used to amplify inserts for pTag(RAR␤ 2 ) and pTag(RAR␤ 4 ), respectively. Amplified products were gel-purified, incubated with BamHI and XbaI, repurified, and ligated into the BamHI and XbaI sites of the pTag vector.
Northern and RT-PCR Analysis of RAR␤ 4 mRNA Expression. Total RNA was obtained from AG11132, Hs578T, MDA-MB-231, MDA-MB-435, MCF-7, and ZR-75-1 cells, and Northern blot analysis was performed on duplicate samples (15 g) (19) . The resulting membrane was divided, and duplicate halves were hybridized with either an RAR␤ 2 -or an RAR␤ 2 ͞ ␤ 4 -specific probe. The RAR␤ 2 probe was the amplification product of pCR(RAR␤ 2 ) with primers 295FP(5Ј-GGCTTT-TAGCTGGCTTGTCTG-3Ј) and 623RP (5Ј-TGAGCAGT-GTGCCGATGCTG-3Ј). The RAR␤ 2 ͞␤ 4 probe was prepared by amplifying pCR(RAR␤ 2 ) with primers 110FP and 259RP (5Ј-GGCTTGCTCGGCCAATCCAG-3Ј). The location of isoform-specific probes is depicted in Fig. 3 . Probes were gel-purified and labeled by random priming in the presence of [␣-32 P]dCTP. Probes were hybridized to the membranes overnight at 65°C with 4 ϫ 10 5 cpm͞ml of the radiolabeled probe in a solution of 1% SDS, 1 M sodium chloride, 10% dextran sulfate and 66.7 g͞ml sheared salmon sperm DNA. Membranes were washed twice in 0.1ϫ SSC͞0.5% SDS at 65°C for 30 min, after which autoradiographs were produced. The PstI fragment of a plasmid containing a 36B4 insert (21) was used as a loading control probe.
Total RNA (5 g) was analyzed by RT-PCR. After an initial RT from primer 1008RP (5Ј-GAGATCGTCCAACTCAGCTG-3Ј), nested PCR using primers spanning the unique RAR␤ 4 splice junction [26FP and 1008RP, then 110FP and 933RP (5Ј-CCTGTCATTCCTGACAGAT-3Ј)] was performed. In the first round of PCR, 1 l of the RT reaction was amplified with Taq DNA polymerase (Roche Molecular Biochemicals, Indianapolis, IN), 35 cycles at 94°C (30 sec), 60°C (30 sec), and 72°C (1 min 30 sec). Two microliters of the first reaction was amplified with the second primer set, 40 cycles at 94°C (30 sec), 62°C (30 sec), and 72°C (1 min 15 sec). Duplicates of each sample were separated on agarose gels and then transferred onto a membrane. The duplicate membranes were probed with a radiolabeled oligonucleotide complementary either to the RAR␤ 2 sequence only (295FP) or to both the RAR␤ 2 and RAR␤ 4 isoforms (158FP; 5Ј-TCCGGAACGCATTCGGAAGG-3Ј). Hybridization and wash conditions were as described (22) .
Nuclear and Cytoplasmic Extracts. Nuclear extracts were obtained as described (7). The cytoplasmic fraction was also collected, i.e., the supernatant obtained after Dounce homogenization in buffer A and pelleting of the nuclear fraction. The cytoplasmic fraction was cleared by centrifugation at 24,000 ϫ g at 4°C for 2 hr and dialyzed against 100 vol of buffer D. Both nuclear and cytoplasmic protein extracts were frozen in ethanol͞dry ice and stored at Ϫ80°C. SDS͞PAGE and Immunoblotting. In vitro translations were performed with the TnT SP6-coupled reticulocyte lysate (Promega). One microliter of in vitro translation product or 7 g of nuclear and cytoplasmic extracts were separated in duplicate on 12% SDS͞PAGE and stained for total protein (SYPRO Orange, Bio-Rad) or blotted to a poly(vinylidene difluoride) membrane. The membrane was blocked in 1% nonfat dry milk (Bio-Rad) in PBS with 0.1% Tween-20 (PBS-T) for 1 hr at room temperature, followed by incubation with either an RAR␤ primary antibody (sc-552X; Santa Cruz Biotechnology) or a p170 topoisomerase II primary antibody (TopoGEN, Columbus, OH) at 1:1000 in PBS-T (1 hr). After four washes with PBS-T (5 min), the membrane was incubated with a horseradish peroxidase-conjugated anti-rabbit secondary antibody at 1:2000 in PBS-T (1 hr). The blot was visualized by chemiluminescent detection (Pierce).
Immunocytochemistry of Transiently Transfected Cells. Cells were plated at 2 ϫ 10 5 to 3 ϫ 10 5 cells per 9-cm 2 glass chamber slide and incubated for 1 to 2 days. For tumor cells, chamber slides were first coated with FBS 30 min before plating. Cells were transfected with 2.5 g of construct DNA using Superfect reagent (Qiagen, Valencia, CA). After fixation in cold 50% acteone͞50% methanol (5 min), slides were incubated with 1% FBS in PBS (F-PBS) for 5 min. Antibody incubations were performed at room temperature for 1 hr. The primary anti-(His) 6 antibody (Invitrogen) was used at a 1:1000 dilution in F-PBS. A secondary antibody, FITC-conjugated goat anti-mouse antibody (Caltag, Burlingame, CA) was used at a 1:250 dilution in F-PBS. Slides were stained with 50 ng͞l 4Ј,6-diamidino-2-phenylindole. Images analysis, including de- convolution by epifluorescence with an air-cooled SenSys camera and IP LAB SPECTRUM software (Signal Analytics, Vienna, VA) was performed as described (23) .
RESULTS
A Low Molecular Weight RAR␤ Protein in Tumor Cells. When Western blot analyses of known RARE-binding proteins were performed, we observed a striking difference in proteins with immunoaffinity for the RAR␤ antibody between the tumor and the normal cell protein extracts (Fig. 1) . All breast tumor cells (five of five) contained two RAR␤ proteins with molecular masses of approximately 58.8 (53.0-64.7) kDa and 40.6 (36.5-44.7) kDa, compared with the single RAR␤ protein of 48.8 (44.0-53.7) kDa found in normal HMECs. The protein size range in parenthesis reflects a 10% margin of error for our molecular mass standards. The RAR␤ antibody was raised against amino acids at the C terminus, a region common among human RAR␤ isoforms (16) . The molecular mass of RAR␤ 2 is predicted to be 50 kDa on the basis of amino acid sequence; this mass is close to the size seen in the normal HMEC nucleus. We have also observed the above-mentioned RAR␤ isoforms in breast tumor cell and normal HMEC proteins extracted from separate cell cultures. Preincubation of the RAR␤ antibody with a 5-fold excess (by weight) of the RAR␤ peptide used to generate the antibody completely abolished immunodetection of all three RAR␤ isoforms, confirming the specificity of our assay (data not shown). A p170 topoisomerase II immunoblot was used to confirm the presence and specificity of nuclear proteins in our tumor cell extracts. Because this protein is a marker of proliferating cells, its expression in nuclear proteins from tumor cells and normal cells is not expected to be equivalent. We can readily detect other nuclear proteins (e.g., RXR␣, RAR␣) in the nuclear protein fraction of the normal AG11132 cells (data not shown).
The Putative Human RAR␤ 4 mRNA Is Identified in Mammary Cells. In previous experiments, two RAR␤ transcripts (Ϸ3.1 kb and Ϸ2.8 kb) were observed in normal HMECs and breast tumor cell lines when probed with a pan-RAR␤ probe (7). RT-PCR was used to amplify exons 5 through 12 of the RAR␤ gene from the breast tumor cell line MDA-MB-435 and from normal HMEC AG11132. In both cells, two products were observed: one the expected size of Ϸ2 kb and the other Ϸ350 bp shorter. Sequence analysis of the amplicons revealed the deletion of nucleotides ϩ269 through ϩ625 from the shorter product. Other than this deletion, there were no nucleotide alterations between ϩ110 and ϩ2107 (relative to the RAR␤ 2 transcript) when the smaller cDNA was compared with the RAR␤ 2 transcript. This region includes the sequence encompassing the entire RAR␤ 2 protein coding region. Nucleotides deleted from this isoform correspond exactly to those of a putative human RAR␤ 4 splice junction (24) .
mRNA Expression of Human RAR␤ 4 in Mammary Cells. When probed with a portion of the sequence spliced from RAR␤ 2 in the novel isoform, a single Ϸ3.1-kb RAR␤ 2 transcript was detected in Northern blots of HMEC and tumor cell lines (Fig. 2A) . RAR␤ 2 and the shorter (by approximately 350 bp) RAR␤ 4 species are observed when blots were hybridized with a probe complementary to the 5Ј untranslated region (UTR) that is specific for both RAR␤ 2 and RAR␤ 4 transcripts (Fig. 2 A) . RAR␤ 2 and RAR␤ 4 mRNAs were expressed at high levels in Hs578T and MDA-MB-435 breast tumor cells, and at lower levels in normal HMEC AG11132 and ZR-75-1 tumor cells. These expression results are highly repeatable with RNA derived from different cell cultures. RT-PCR, a more sensitive method of detecting RAR␤ 2 and RAR␤ 4 expression (Fig. 2B) , confirmed the presence of RAR␤ 2 and RAR␤ 4 in the above cell lines and the lack of significant levels of these transcripts in the MCF-7 and MDA-MB-231 cell lines. The RAR␤ coding sequence can be detected reliably in these latter cells by using alternative primer sets that do not discriminate between RAR␤ 2 and RAR␤ 4 (e.g., 295FP and 1863RP, followed by 730FP and 1366RP, the primer names indicating the position in nucleotide 5Ј of the RAR␤ 2 transcription start site). Subsequent sequence analysis of genomic Membranes were subsequently stripped and rehybridized with 36B4, a loading control. (B) RAR␤2 and RAR␤4 expression was analyzed by using a sensitive RT-PCR assay. The region amplified spans the RAR␤4 splice junction. RNAs used in this experiment were separate aliquots of the same RNA used in the Northern blot assay. After transfer onto a membrane, blots were hybridized with an oligonucleotide specific for RAR␤2 or for RAR␤2͞␤4, followed by autoradiography. The sizes of the resulting bands are indicated to the right. Passages 19 and 9 (p19, p9) were examined in the normal HMECs.
RAR␤ from these two cell lines, between Ϫ800 and ϩ490, relative to the start of transcription (including the entire RAR␤ 2 5Ј UTR) showed no nucleotide alterations.
The Human RAR␤ 4 Protein Uses a Translation Start Site Within the DNA-Binding Domain. The RAR␤ 2 translation initiation site is within the sequence spliced from the RAR␤ 4 mRNA (Fig. 3) . The 5Ј-most AUG of the RAR␤ 4 transcript that is in-frame with the RAR␤ coding sequence is located at nucleotide 448 of the RAR␤ 4 mRNA and corresponds to the methionine at amino acid 113 of the RAR␤ 2 protein. This AUG is within an appropriate nucleotide context for translation initiation (25) and would result in an ORF of 335 aa with an estimated molecular mass of 38 kDa. The mouse RAR␤ 4 protein initiates translation at a CUG that begins at nucleotide 259 of the mouse RAR␤ 4 transcript (24) . There is an analogous CUG in the human RAR␤ 4 transcript within a nucleotide sequence that is similar to that of the mouse (86% identity within the surrounding 50 bp). If this CUG is used to initiate translation of the human transcript, the resulting protein would be 399 aa long and in-frame with the RAR␤ 2 coding sequence, with an estimated molecular mass of 45 kDa.
To ascertain the position of the translation start site generating the endogenous 40.6-kDa RAR␤ protein observed in breast tumor cell lines, the entire coding sequence of these two candidate translation start sites and 9 bp of the adjacent 5Ј untranslated region were cloned downstream of an SP6 promoter [pSP-(RAR␤ 4 448) and pSP(RAR␤ 4 259wt), respectively]. We also constructed clones with the RAR␤ 2 coding sequence [pSP-(RAR␤ 2 )] for comparison, and constructed a version of pSP(RAR␤ 4 259wt), with the initial CUG mutated to AUG to ensure in vitro initiation of translation [pSP(RAR␤ 4 259mut)]. In vitro translation was performed and the sizes of the protein products generated in vitro were compared with the endogenous proteins by using Western blot analysis. Fig. 4 shows that the in vitro translated RAR␤ 2 protein is comparable in size to the higher molecular mass RAR␤ isoform found in the tumor cell extracts (58.8 kDa). The protein generated from pSP(RAR␤ 4 448), containing the putative coding region initiated by the AUG starting at position 448, has an apparent molecular mass identical to the 40.6-kDa protein found endogenously in tumor cell protein extracts. In tumor cells, both RAR␤ 2 and RAR␤ 4 have apparent molecular masses higher than their theoretical masses based on amino acid sequence. The in vitro translation product of pSP(RAR␤ 4 259mut), with a mutant AUG beginning at nucleotide 259 to initiate translation, is approximately 44.0 kDa and does not correspond with the size of any of the endogenous RAR␤ proteins. Translation of pSP(RAR␤ 4 259wt), having the wild-type CUG at nucleotide 259 to initiate translation, resulted primarily in the 40.6-kDa size produced by pSP(RAR␤ 4 448) (Fig. 4) , thereby indicating that the wild type CUG at position 259 does not strongly direct translation initiation. Translation then initiates at the downstream AUG. These data are consistent with translation initiation of the human RAR␤ 4 transcript at the AUG, beginning at nucleotide 448. This AUG is maintained in the cDNA sequence of the two tumor cell lines sequenced (MDA-MB-435 and ZR-75-1) and in the normal AG11132 cDNA.
The RAR␤ 4 Protein Localizes to the Nucleus and Cytoplasm. To verify that the protein product of the RAR␤ 4 transcript is capable of nuclear translocation, we performed fluorescent immunocytochemistry on cells that were transiently transfected with (His) 6 -tagged RAR␤ proteins. The human RAR␤ 2 and RAR␤ 4 coding sequences were cloned into the mammalian expression vector pTag. These constructs [pTag(RAR␤ 2 ) and pTag(RAR␤ 4 )] were transiently transfected into normal HMECs and MDA-MB-231 breast tumor cells. Subsequent immunocytochemistry with a monoclonal anti-(His) 6 antibody confirmed the presence of RAR␤ 4 within the nuclear fraction that was observed by Western blot anal- 
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Medical Sciences: Sommer et al. Proc. Natl. Acad. Sci. USA 96 (1999) ysis. The majority of the (His) 6 -RAR␤ 4 protein in both normal and tumor cells ( Fig. 5B and E, respectively) is cytoplasmic, in patterns resembling cytoskeletal staining. The nuclear signal of the (His) 6 -RAR␤ 4 transfected cells was punctate in both cell lines and ranged from multiple small dots to larger, coalescing clusters. Deconvolution of the AG11132 cells that were transiently transfected with pTag(RAR␤ 4 ) confirmed the localization of the FITC punctate signal to the nucleus (Fig. 5C ). As expected, the exogenous (His) 6 -RAR␤ 2 protein localized primarily to the nucleus of both normal (Fig. 5A ) and tumor (Fig.  5D ) cells. The nuclear staining pattern of (His) 6 -RAR␤ 2 appeared to be uniform throughout the nucleoplasm.
DISCUSSION
Two RAR␤ proteins were detected in the nuclei of breast tumor cell lines; these proteins had molecular masses distinctly different from the single RAR␤ protein found in the normal HMEC nucleus. It is probable that the 48.8-kDa species in normal cells is RAR␤ 2 , on the basis of its size and the presence of the RAR␤ 2 mRNA. This is also the size observed in Western blot analyses of human RAR␤ 2 (26) and of the mouse RAR␤ 2 (27) . We have determined that the 40.6-kDa isoform seen in breast tumor cells is human RAR␤ 4 (see discussion below). The 58.8-kDa RAR␤ species found exclusively in breast tumor cells has an electrophoretic mobility identical to RAR␤ 2 generated by in vitro translation. It is possible that this 58.8-kDa species represents posttranslationally modified RAR␤ 2 . Other investigators have described phosphorylation of the mouse RAR␤ 2 during in vitro translation with rabbit reticulocyte lysates (27) . RAR␤ 2 transcripts were detected in three of the five breast tumor cell lines examined, and these cell lines contained only the 58.8-kDa RAR␤ in addition to RAR␤ 4 . Only two RAR␤ transcripts can be observed in these cells with a pan-RAR␤ probe (7) . By hybridizing Northern blots with specific RAR␤ 2 or RAR␤ 2 ͞ RAR␤ 4 probes, these two transcripts were identified as RAR␤ 2 and RAR␤ 4 ( Fig. 2 A) . Although Nagpal et al. (24) described the exon-5͞exon-6 junction of a putative human RAR␤ 4 cDNA over 6 years ago, neither a complete analysis of the RAR␤ 4 mRNA nor a reported human RAR␤ 4 protein product has been reported. Other investigators have detected a portion of the putative RAR␤ 4 transcript in lung tissue and in lung carcinoma cell lines (28) . Here we describe the human RAR␤ 4 transcript more extensively; we identify its protein product, which is expressed endogenously in human breast tumor cell lines. The RAR␤ 4 mRNA is probably generated by splicing of the nascent RAR␤ P2 transcript by means of an alternative exon-5 splice donor to that used to create RAR␤ 2 . Both RAR␤ 2 and RAR␤ 4 contain exon-5 sequence that is specific for P2 transcription.
There is compelling evidence that RAR␤ 2 and RAR␤ 4 are posttranscriptionally regulated in breast epithelial cells. This appears dramatically when the protein and RNA levels in the MCF-7 cell line are compared with those in the MDA-MB-231 line (Figs. 1 and 2) . Expression of RAR␤ 2 and RAR␤ 4 mRNA is undetectable by Northern analysis (Fig. 2 A) and can be observed only by RT-PCR. Surprisingly, RAR␤ 2 and RAR␤ 4 proteins are present in these same cells at levels comparable to those cells with relatively high levels of the transcripts (e.g., MDA-MB-435) (Fig. 1) . Conversely, although normal HMECs transcriptionally express RAR␤ 4 , the RAR␤ 4 protein is not detected in these cells by Western blot assays. These two pieces of data suggest differential protein synthesis or stability for RAR␤ 4 between normal HMECs and breast cancer cells.
Sequence analysis of the RAR␤ 4 5Ј untranslated region revealed the presence of 5 uORFs (Fig. 6) . uORFs occur when AUGs are present 5Ј of the coding sequence initiation site. According to the scanning model of translation, a 40S preinitiation complex binds the mRNA cap site and proceeds in the 3Ј direction until reaching the first AUG that is within an adequate nucleotide context for translation initiation (29) . Translation then proceeds until an in-frame stop codon is reached. Depending on uORF length and intercistronic distance, reinitiation of translation at a downstream AUG may occur (29, 30) . Because reinitiation is inefficient, the presence of AUG sites in the 5Ј leader sequence is inhibitory to translation at downstream coding regions. Whereas upstream AUG sequences occur only rarely in mRNA transcripts, those having this mRNA structure are important regulators of cellular growth and differentiation, i.e., tumor suppressors, oncogenes, homeobox genes, and cell cycle control genes (31) . uORFs, then, may provide an additional level of regulation for genes that are critical to the maintenance of cellular homeostasis. In human RAR␤ 4 of these uORFs would proceed out-of-frame and past the RAR␤ 4 translation start site. For RAR␤ 4 translation to occur, initiation at uORFs 3 and 4 must be bypassed. We hypothesize that the lack of RAR␤ 4 protein in normal HMECs results from tight inhibition of translation through these uORFs. Conversely, the presence of RAR␤ 4 protein in breast tumor cells with low transcript levels might indicate that these cells have evolved mechanisms of escaping this translational control. It has been shown that RAR␤ 2 uORFs translationally regulate the mouse RAR␤ 2 gene in a tissue-specific manner (32) . Underscoring the presence of aberrant translational controls in certain breast tumor cell lines, a 33-kDa RAR␤ protein present in MDA-MB-231 cytoplasmic extracts (Fig. 1) corresponds to translation initiation at an internal AUG, beginning at nucleotide 545 of the RAR␤ 4 mRNA.
The CUG sequence starting at nucleotide 259 of the mouse RAR␤ 4 transcript directs translation initiation in COS-1 cells (24) . We have determined that the analogous CUG in the human isoform does not appear to be recognized as an initiation site by the human translation machinery in vivo or by rabbit reticulocyte lysates in vitro, despite an 86% sequence identity. Instead, it is likely that translation of the RAR␤ 4 protein in breast tumor cells initiates at nucleotide 448 of the RAR␤ 4 mRNA. The resulting RAR␤ 4 protein consists of the C-terminal 335 aa of RAR␤ 2 . While maintaining the hinge region and its putative nuclear localization signal, the ligandbinding͞dimerization domains, and the C-terminal transcription activation region (AF-2), the resulting human RAR␤ 4 protein lacks half of the DNA-binding domain, including one of two zinc fingers, and the entire N-terminal transcription activation domain (AF-1) of RAR␤ 2 (Fig. 3) . The protein product of the human RAR␤ 4 mRNA is therefore quite different from the protein product generated in the mouse; in the mouse, it is identical to RAR␤ 2 , with the exception of a unique A region of 4 aa (24) .
Although the human RAR␤ 4 lacks a complete DNA-binding domain and an AF-1 region, it retains domains required for ligand binding, dimerization, and interactions with nuclear receptor cofactors. Additionally, we show that RAR␤ 4 is selectively expressed at the protein level in breast tumor cells and that it is capable of nuclear localization. We hypothesize that RAR␤ 4 in the tumor cell nucleus maintains the ability to interact with RXR heterodimers and essential coactivators of the transcription machinery, sequestering these factors from transcriptionally productive interactions with RARs binding at target RAREs.
